Leonard Zehr, Author at BioTuesdays

Feature

Ritter Pharma aims to have first FDA-approved treatment for lactose intolerance

By Len Zehr Ritter Pharmaceuticals’ (NASDAQ:RTTR) lead product candidate, RP-G28, which recently entered Phase 3 clinical trials, has the potential to become the first prescription therapy for lactose intolerance, a...

September 4, 2018

Feature

Vasomune finds nice fit in co-development pact for vascular leakage with AnGes

Closely-held Vasomune Therapeutics found the right partner last month in AnGes (TYO:4563) to co-develop its Vasculotide drug candidate for the treatment of diseases associated with blood vessel leakage and pulmonary...

August 28, 2018

Feature

Evoke Pharma’s Gimoti NDA targets female gastroparesis patients with novel delivery approach

By Len Zehr Evoke Pharma’s (NASDAQ:EVOK) discovery that its metoclopramide nasal spray, known as Gimoti, to treat symptoms of gastroparesis, a delayed emptying of stomach contents, reduced symptoms in women, but not in...

August 21, 2018

Feature

Exicure readies two clinical data readouts later this quarter

By Len Zehrs Exicure (OTCQB:XCUR) expects to report data around the end of the third quarter of 2018 from two Phase 1 clinical trials, one in mild-to-moderate psoriasis and one in healthy volunteers with its lead...

August 7, 2018

Feature

Perimeter pioneering high resolution wide-field tissue imaging for tumor specimens

By Len Zehrs Closely-held Perimeter Medical Imaging’s next-generation wide-field optical coherence tomography (OCT) technology for tumor tissue specimens has imaging resolution 10 times higher than ultrasound and 100...

July 31, 2018

Feature

ASLAN Pharma gears up for data rich second half

By Len Zehrs ASLAN Pharmaceuticals (NASDAQ:ASLN; TPEx:6497) expects to report topline and interim data in the second half of 2018 from up to four clinical trials with its lead drug candidate, varlitinib, for the...

July 24, 2018

Feature

Centurion BioPharma targeting strategic alliance for LADR drug conjugates by year’s end

By Len Zehrs Centurion BioPharma, a newly-created private subsidiary of CytRx (NASDAQ:CYTR), is currently in discussions with a number of pharma companies for a strategic alliance to continue development of its patient...

July 10, 2018

Feature

Intellijoint Surgical setting new standard in surgical 3D navigation

By Len Zehrs Closely-held Intellijoint Surgical plans to improve patients’ lives by providing every orthopaedic surgeon with their surgical 3D solution that provides real-time intraoperative measurements to ensure...

July 3, 2018

Feature

Kardium seeking CE Mark for breakthrough treatment of atrial fibrillation

By Len Zehrs Closely-held Kardium hopes to receive marketing approval in Europe in the fourth quarter of 2018 and launch its breakthrough Globe mapping and ablation system of cardiac tissue for the treatment of atrial...

June 26, 2018

Feature

Imagin Medical taking bladder cancer imaging to next level

By Len Zehrs Imagin Medical’s (CSE:IME; OTC:IMEXF) i/Blue Imaging System is expected to improve physicians’ ability to detect bladder cancer with minimally invasive endoscopes and reduce recurrence by dramatically...

June 19, 2018

Author - Leonard Zehr

Ritter Pharma aims to have first FDA-approved treatment for lactose intolerance

Vasomune finds nice fit in co-development pact for vascular leakage with AnGes

Evoke Pharma’s Gimoti NDA targets female gastroparesis patients with novel delivery approach

Exicure readies two clinical data readouts later this quarter

Perimeter pioneering high resolution wide-field tissue imaging for tumor specimens

ASLAN Pharma gears up for data rich second half

Centurion BioPharma targeting strategic alliance for LADR drug conjugates by year’s end

Intellijoint Surgical setting new standard in surgical 3D navigation

Kardium seeking CE Mark for breakthrough treatment of atrial fibrillation

Imagin Medical taking bladder cancer imaging to next level

General

More